Investigational drug · Phase 3
Bisphosphonate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Osteogenesis Imperfecta.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
761
Any phase or sponsor naming "Bisphosphonate"
First trial start
2023
Jun 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bisphosphonate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteogenesis Imperfecta
Largest trials
Live from ClinicalTrials.gov: studies naming "Bisphosphonate" as an intervention, largest first.
Organon and CoIndustry
NCT01077817 · 684,815 participants · Start Feb 26, 2010 · Primary completion Feb 16, 2012
Drug: Alendronate; Etidronate and 3 more · For: Esophageal Cancer; Squamous Cell Carcinoma; Adenocarcinoma
AmgenAmgen (AMGN)
NCT02520362 · 517,991 participants · Start May 31, 2010 · Primary completion Jul 21, 2023
Drug: denosumab; bisphosphonate · For: Osteoporosis
National Cheng-Kung University HospitalAcademic, hospital or other
NCT05366621 · 216,155 participants · Start Nov 1, 2020 · Primary completion Sep 30, 2021
Drug: Anti-osteoporosis medications · For: Osteoporosis; Osteoporosis Fracture; Drug Therapy and 2 more
Sites: Tainan, Taiwan
National Defense Medical Center, TaiwanAcademic, hospital or other
NCT05623540 · 27,405 participants · Start Jan 1, 2000 · Primary completion Dec 31, 2015
Drug: Bisphosphonates, Combinations · For: Diphosphonates
Sites: Taipei, Taiwan
- Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims DataPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT04736693 · 18,028 participants · Start Sep 22, 2020 · Primary completion Feb 18, 2021
Drug: Raloxifene; Zoledronic Acid · For: Osteoporosis
Sites: Boston, Massachusetts
Brigham and Women's HospitalAcademic, hospital or other
NCT04879420 · 12,757 participants · Start Oct 29, 2020 · Primary completion Jun 11, 2021
Drug: Teriparatide; Risedronate · For: Osteoporosis
Sites: Boston, Massachusetts
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
PfizerPfizer (PFE)
NCT01416194 · 10,497 participants · Start Jul 25, 2011 · Primary completion Apr 30, 2019
Drug: Bazedoxifene; Bisphosphonate and 1 more · For: Osteoporosis, Postmenopausal
- HORIZON-PFT: Pivotal Fracture TrialPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00049829 · 7,700 participants · Start Jan 2002 · Primary completion Jun 2006
Drug: Zoledronic Acid · For: Osteoporosis
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Tucson, Arizona · 60 sites in all
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00127205 · 6,097 participants · Start Jul 2005 · Primary completion Dec 2017
Drug: clodronate disodium; ibandronate sodium and 1 more · For: Breast Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Chemically tailored lipids mediate solid-phase RNA programming of mineralized microenvironments.
Liu J, Chen Q, Thussananutiyakul J, et al. · Biomaterials 2027
- Alendronate alters mineral composition and has potential to restore enthesis strength without preventing trabecular bone loss during unloading of the supraspinatus enthesis.
Whittaker S, De Bruyker I, Hemanth N, et al. · Bone 2027
- Skeletal effects of 5-year high-dose cyclical etidronate in patients with pseudoxanthoma elasticum.
Haverkamp M, van Weert AJ, Foppen W, et al. · Bone 2027
- Contralateral atypical femoral fracture following a single dose of denosumab after incomplete teriparatide therapy in a patient with long-term bisphosphonate exposure: A case report.
Lee DH · Bone Rep 2026
- Early-onset medication-related osteonecrosis of the jaw in adolescents with Duchenne muscular dystrophy receiving long-term antiresorptive combined with glucocorticoid therapy: Two case reports.
Rio A, Olivier P, Leblicq C, et al. · Bone Rep 2026
- Application of recombinant human bone morphogenetic protein-2 for the surgical management of Medication-Related Osteonecrosis of the Jaw in patients with osteoporosis.
Jin MX, Cho KJ, Choi SY, et al. · J Craniomaxillofac Surg 2026
Also in development for Osteogenesis Imperfecta
- SetrusumabBPS804, UX143Phase 33 trials
Ultragenyx Pharmaceutical Inc · Osteogenesis Imperfecta
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.